ERBB2 and cancer: Unlike their HER2-positive counterparts, LF/HF ratio and cellular oxidative stress in peripheral blood mononuclear cells of HER2-negative cancer patients were significantly increased 2 weeks after completion of doxorubicin treatment (Fig. 3C, F).